Literature DB >> 8951685

Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbits.

T Taniguchi1, M S Haque, K Sugiyama, N Hori, Y Kitazawa.   

Abstract

This study was performed to clarify the ocular hypotensive mechanism of topical isopropyl unoprostone (unoprostone), a novel prostaglandin (PG) metabolite-related drug, in the rabbit eye. The intraperitoneal administration of indomethacin (50 mg/kg) 1 hour before administration of topical 0.12% unoprostone partially diminished the intraocular pressure (IOP) reduction, and completely blocked the increase in aqueous PGE2 concentration caused by unoprostone. Aqueous humor dynamics measurements in the unoprostone- and the vehicle-treated contralateral eyes with indomethacin pretreatment revealed that aqueous flow determined by fluorophotometry was not significantly different, 2.3 +/- 0.3 and 2.4 +/- 0.2 microliters/min, respectively; the total outflow facility measurements determined by the two-level constant pressure perfusion method were 0.20 +/- 0.01 and 0.14 +/- 0.01 microliters/min/mmHg, respectively (p < 0.05); the uveoscleral outflow measurements determined by the fluorescein isothiocyanate-dextran perfusion method were 0.49 +/- 0.02 and 0.46 +/- 0.02 microliters/min, respectively (p < 0.05). The magnitude of the IOP reduction induced by unoprostone was estimated to be 5.2 mmHg, which agrees well with the actual IOP reduction. In conclusion, unoprostone lowers the IOP by affecting aqueous outflow pathways, primarily the pressure-dependent conventional pathway and the secondary uveoscleral outflow pathway in rabbits. Endogenous PGs induced by topical unoprostone are also involved in lowering the IOP in rabbits.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8951685     DOI: 10.1089/jop.1996.12.489

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  14 in total

1.  Effect of topical unoprostone isopropyl on optic nerve head circulation in controls and in normal-tension glaucoma patients.

Authors:  Itaru Kimura; Kei Shinoda; Tomihiko Tanino; Yuichiro Ohtake; Yukihiko Mashima
Journal:  Jpn J Ophthalmol       Date:  2005 Jul-Aug       Impact factor: 2.447

Review 2.  Evolving paradigms in the medical treatment of glaucoma.

Authors:  John S Cohen; Anup K Khatana; Linda J Greff
Journal:  Int Ophthalmol       Date:  2006-03-07       Impact factor: 2.031

3.  Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost in patients with primary open angle glaucoma or ocular hypertension.

Authors:  T Chiba; K Kashiwagi; N Chiba; S Tsukahara
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

4.  Additive effect of unoprostone and latanoprost in patients with elevated intraocular pressure.

Authors:  Tin Aung; Paul T K Chew; Francis T S Oen; Yiong-Huak Chan; Lennard H Thean; Leonard Yip; Boon-Ang Lim; Jade Soh; Steve K L Seah
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

5.  Additional reduction in intraocular pressure achieved with latanoprost in normal-tension glaucoma patients previously treated with unoprostone.

Authors:  Miho Enoki; Jun Saito; Makiko Hara; Tetsuya Uchida; Takeshi Sagara; Teruo Nishida
Journal:  Jpn J Ophthalmol       Date:  2006 Jul-Aug       Impact factor: 2.447

Review 6.  Pharmacological therapy for glaucoma: a review.

Authors:  P F Hoyng; L M van Beek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

7.  Effects of 0.4% ripasudil hydrochloride hydrate on morphological changes in rabbit eyes.

Authors:  Bundit Limratchatamorn; Ken Asakawa; Kimiyo Mashimo; Shigekazu Uga; Hitoshi Ishikawa
Journal:  Int J Ophthalmol       Date:  2019-10-18       Impact factor: 1.779

Review 8.  Prostaglandin analogues in the treatment of glaucoma.

Authors:  C Lindén; A Alm
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

9.  Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide.

Authors:  A Hommer; B Kapik; N Shams
Journal:  Br J Ophthalmol       Date:  2003-05       Impact factor: 4.638

10.  The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice.

Authors:  Takashi Ota; Makoto Aihara; Tadashiro Saeki; Shuh Narumiya; Makoto Araie
Journal:  Br J Ophthalmol       Date:  2006-11-23       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.